Trial | NCT02961725  Report issue

Title

Stem Cells for Treatment of Bronchopleural Fistula
Umbilical Cord Mesenchymal Stem Cells for Treatment of Bronchopleural Fistula

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    10
Bronchopleural fistula (BF), an abnormal passage or communication between a bronchus and another part of the body, may develop when there are penetrating wounds of the thorax and after lung surgery. Without effective therapy, treatment of BF is a challenge, with a high rate of mortality and teratogenicity.

The investigators will conduct endoscopic injection of umbilical cord mesenchymal stem cells to fistula, observe the recovery of bronchopleural fistula and systemic reactions, to investigate the application of umbilical cord mesenchymal stem cells in the treatment of bronchopleural fistula.
Study Started
Apr 30
2016
Primary Completion
Apr 30
2017
Anticipated
Study Completion
Apr 30
2019
Anticipated
Last Update
Nov 11
2016
Estimate

Biological UCMSC

UCMSC: umbilical cord mesenchymal stem cells 3-5*10^7/5 ml

UCMSC treatment Experimental

UCMSC: umbilical cord mesenchymal stem cells

Criteria 

Inclusion Criteria:

diagnosed with bronchopleural fistula by imaging or bronchoscopic examination
typical symptom of bronchopleural fistula, such as fever, cough, purulent sputum, weight loss…
patients present compromised conditions, who can only accept a conservative treatment.

Exclusion Criteria:

absolute contraindication of bronchoscopic examination and treatment
with previous treatment of cell therapy, including stem cells.
No Results Posted